Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014 are as follows:



(In millions)	Generics Segment			Specialty Segment			Total
Balance at December 31, 2013:
Goodwill	$	3,991.4		$	734.1		$	4,725.5
Accumulated impairment losses	—			(385.0		)	(385.0		)
	3,991.4			349.1			4,340.5
Acquisitions	13.3			—			13.3
Divestment	(10.5		)	—			(10.5		)
Foreign currency translation	(294.0		)	—			(294.0		)
	3,700.2			349.1			4,049.3
Balance at December 31, 2014:
Goodwill	3,700.2			734.1			4,434.3
Accumulated impairment losses	—			(385.0		)	(385.0		)
	3,700.2			349.1			4,049.3
Acquisitions	1,658.2			—			1,658.2
Foreign currency translation	(327.4		)	—			(327.4		)
	5,031.0			349.1			5,380.1
Balance at December 31, 2015:
Goodwill	5,031.0			734.1			5,765.1
Accumulated impairment losses	—			(385.0		)	(385.0		)
	$	5,031.0		$	349.1		$	5,380.1

Components of intangible assets

Intangible assets consist of the following components at December 31, 2015 and 2014:



(In millions)	Weighted Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
December 31, 2015
Amortized intangible assets:
Patents and technologies	20	$	116.6	$	103.8	$	12.8
Product rights and licenses	11	8,848.6		2,652.7		6,195.9
Other⁽¹⁾	6	465.3		189.8		275.5
		9,430.5		2,946.3		6,484.2
In-process research and development		737.7		—		737.7
		$	10,168.2	$	2,946.3	$	7,221.9
December 31, 2014
Amortized intangible assets:
Patents and technologies	20	$	116.6	$	99.2	$	17.4
Product rights and licenses	10	3,617.0		2,127.8		1,489.2
Other⁽¹⁾	8	162.2		70.6		91.6
		3,895.8		2,297.6		1,598.2
In-process research and development		748.9		—		748.9
		$	4,644.7	$	2,297.6	$	2,347.1

____________


⁽¹⁾	Other intangibles consist principally of customer lists, contractual rights and other contracts.

Product rights and licenses by therapeutic category

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic category, is as follows:



(In millions)	December 31, 2015		December 31, 2014
Allergy	$	71.2	$	82.5
Anti-infectives	368.7		152.8
Antineoplastic	169.3		123.7
Cardiovascular	1,105.5		175.0
Central Nervous System	949.8		199.5
Dermatological	52.9		65.9
Endocrine and Metabolic	1,152.5		54.8
Gastrointestinal	1,289.9		67.6
Hematological Agents	370.1		294.5
Immunological Agents	322.7		20.8
Respiratory System	137.9		78.3
Other⁽¹⁾	205.4		173.8
	$	6,195.9	$	1,489.2

____________


⁽¹⁾	Other consists of numerous therapeutic classes, none of which individually exceeds 5% of total product rights and licenses.